NCT00574405View on ClinicalTrials.gov

Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2011

Conditions
Diabetes Mellitus
Interventions
DRUG

MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])

MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.

DEVICE

CSII (Animas Corporation insulin pump, model IR 1200)

CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.

Trial Locations (1)

72202

Arkansas Children's Hospital/Research Institute, Little Rock

All Listed Sponsors
lead

Arkansas Children's Hospital Research Institute

OTHER

NCT00574405 - Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy | Biotech Hunter | Biotech Hunter